An ideal case example of this working would be for the available generics and biosimilars that we have in the multiple sclerosis therapeutic area; these medications often have lower list prices than ...

Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...

Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...

Dr. Barot joins an already accomplished team of medical experts at ADIA Nutrition, bringing with him a wealth of knowledge ...

B.Riley Financial analyst William Wood has reiterated their bullish stance on IMUX stock, giving a Buy rating on September 16. William Wood ...

Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE ...

Gaps in access to care persist for US patients with MS and impact HRQOL to a large extent. Improving access to care for patients with MS should be prioritized.

Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive ...

Dr. Elizabeth Gromisch discusses her study, which showed the feasibility of a telehealth intervention for teaching ...

The meeting was part of the Authority’s strategy to strengthen partnerships with global pharmaceutical companies to provide ...

In a significant advance for multiple sclerosis (MS) research, a new study has uncovered a potential link between certain initial symptoms and ...